Loading...
| A01209 | Pages: 120 | Apr 2017 | 26404 Views | | |
| Author(s) : Onkar Sumant and Tenzin Kunsel | Tables: 55 | Charts: 58 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Sleep Aids Market
Request Now !The sleep aids market size was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2023, registering a CAGR of 7.0% from 2017 to 2023. Sleep is a biological requirement that maintain metabolic homeostasis, influences memory and other cognitive function, and regulates immune function. Sleep aids are drugs and medical devices that are used to diagnose and treat various sleep disorders, such as sleep apnea and insomnia. Lack of quality sleep leads to sleep disorders, which are caused due to medical problems, physical disturbances, environmental problems, and psychiatric disorders. These sleep disorders are expected to adversely affect the human health and lead to number of chronic diseases, such as high blood pressure, diabetes, arthritis, and stroke. Thus, it is important to treat and diagnose these disorders at an early stage. In addition, rising innovations in sleep aid devices, developing drugs for inappropriate sleep and rising utilization of compact sleep apnea devices is relied upon to add to the development of the global sleep aids market.
It is believed that the level of obesity increases and the Americans ages, more people are being strengthened with sleep disorders, uncomfortable leg syndrome and other sleep apnea. In addition, the stress in 2020 pandemic of Covid-19 and the recession contribute to the most vulnerable nights.
Get more information on this report : Request Sample Pages
It is estimated that between 50 to 70 million Americans suffer from sleep disorders, 30% of the population have short-term problems, and the majority are undiagnosed. Given that obesity rates remain high, this problem is unlikely to go away anytime soon. Therefore CPAP Devices, Sleep Research Study, Prescription Drugs, Over-The-Counter (OCT) drugs, and other services have ample room for future growth in coming years.
The global Sleep Aids Market is segmented based on product, sleep disorder, and geography. Based on product, it is classified into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medication segment is further divided into prescription-based drugs, over-the-counter (OTC) drugs, and herbal drugs. Based on sleep disorder, it is categorized into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorders. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get more information on this report : Request Sample Pages
Drivers, Restrains, and Opportunities
The impact of the driving factors is expected to surpass the effect of restraints. Moreover, the increase in awareness about sleep disorders and technological advancements are expected to provide new market opportunities to sleep aids manufacturers in the near future.
Other factors contributing to the growth of the sleep market includes driving age, stressful working hours, increase in consumption of alcohol and tobacco, and changing lifestyles. Delayed diagnosis can lead to chronic conditions such as risk of heart failure, stroke, high blood pressure, diabetes, and obesity. The increasing trend towards the using over-the-counter (OTC) drugs and devices for monitor, diagnose, and treatment of sleep disorders is expected to stimulate the demand for sleep-aiding drugs and devices.
Get more information on this report : Request Sample Pages
Global Sleep Aids Market Key Geographical Segment
North America accounted for the highest sleep market share in 2016, and is expected to maintain its dominance throughout the forecast period.
Some of the key players operating in the global sleep aids market are Koninklijke Philips N.V., Merck & Co., Sanofi, eVilbiss Healthcare LLC., Pfizer Inc., SleepMed Inc., Cadwell Laboratories Inc., Compumedics Limited, Natus Medical Incorporated, and GlaxoSmithKline plc.
The other significant players in the value chain include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, CareFusion Corporation, Tempur-Pedic Management Inc., Serta International, and Drive Medical Ltd.
Get more information on this report : Request Sample Pages
Key Benefits for Stakeholders:
This report provides an extensive analysis of the current and emerging market trends and dynamics in the global sleep aids market to identify the prevailing opportunities.
The major countries in North America have been mapped according to their individual revenue contribution to the regional market
This study presents the competitive landscape of the global sleep market to predict the competitive environment across geographies.
Porter’s five forces analysis helps to analyze the potential of the buyers & suppliers and the competitive scenario of the industry for strategy building
The sleep aids market size for product is mentioned in the report in terms of revenue and volume
It outlines the current trends and future scenario of the market from 2016 to 2023 to understand the prevailing opportunities and potential investment pockets
The key drivers, restraints, and opportunities and their detailed impact analyses are elucidated in the study
The profiles of key players along with their key strategic developments are enlisted in the report
Sleep Aids Market Key Segments:
By Product
Mattresses & Pillows
Sleep Laboratories
Medications
Prescription-based Drugs
OTC drugs
Herbal drugs
Sleep Apnea Devices
By Sleep Disorder
Insomnia
Sleep Apnea
Restless Legs Syndrome
Narcolepsy
Sleep Walking
Other Sleep Disorders
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Republic of South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Astrazeneca Plc (Astrazeneca)
Biodiem
Csl Limited (Seqirus GmbH)
Emergent Biosolutions
F. Hoffmann-La Roche Ltd.
Gamma Vaccines Pty Ltd.
Glaxosmithkline Plc
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Novartis Ag
Pfizer, Inc.
Sanofi
Sinovac Biotech Ltd.
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY BENEFITS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PATENT ANALYSIS
3.3.1. Patent analysis by year
3.3.2. Patent analysis by region
3.3.3. Patent analysis by sleep disorder
3.4. GOVERNMENT REGULATIONS
3.4.1. U.S. FDA
3.4.2. Europe CE Mark
3.4.3. Ministry of Health, Labor, and Welfare (MHLW)
3.5. TOP PLAYERS POSITIONING, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Modern lifestyle increases the risk of sleep disorders
3.6.1.2. Stressful Work Condition and Working in Shifts
3.6.1.3. Rise in geriatric and obese population
3.6.2. Restraints
3.6.2.1. Adverse effects of sleep aid medication
3.6.2.2. Patent expiration
3.6.3. Opportunities
3.6.3.1. Technological Advancements Leading to Better Adoption
3.6.3.2. Untapped Markets in Developing Economies
CHAPTER 4 GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. MATTRESSES AND PILLOWS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. SLEEP LABORATORIES
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. MEDICATIONS
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Prescription-based drugs
4.4.5. OTC drugs
4.5. SLEEP APNEA DEVICES
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 SLEEP AIDS MARKET, BY SLEEP DISORDER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. INSOMNIA
5.2.1. Market size and forecast
5.3. SLEEP APNEA
5.3.1. Market size and forecast
5.4. RESTLESS LEGS SYNDROME
5.4.1. Market size and forecast
5.5. NARCOLEPSY
5.5.1. Market size and forecast
5.6. SLEEPWALKING
5.6.1. Market size and forecast
5.7. OTHERS
5.7.1. Market size and forecast
CHAPTER 6 SLEEP AIDS MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Rest of Europe market size and forecast
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. CADWELL INDUSTRIES INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. COMPUMEDICS LIMITED
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. DRIVE DEVILBISS HEALTHCARE
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. GLAXOSMITHKLINE PLC
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. MERCK & CO., INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. NATUS MEDICAL INCORPORATED
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6.6. Key strategic moves and developments
7.7. PFIZER INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. KONINKLIJKE PHILIPS N.V.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. SANOFI
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.10. SLEEPMED INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 2. SLEEP AIDS MATTRESS AND PILLOWS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. SLEEP AIDS SLEEP LABORATORIES MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. SLEEP AIDS MEDICATIONS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. SLEEP AIDS PRESCRIPTION-BASED DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. SLEEP AIDS OTC DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. GLOBAL SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 8. INSOMNIA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. SLEEP APNEA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. RESTLESS LEGS SYNDROME SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 11. NARCOLEPSY SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. SLEEPWALKING MEDICAL SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. OTHER SLEEP DISORDERS SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. NORTH AMERICA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18. EUROPE SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 19. EUROPE SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 20. EUROPE SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 21. EUROPE SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. ASIA-PACIFIC SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 23. ASIA-PACIFIC SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 24. ASIA-PACIFIC SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 25. ASIA-PACIFIC SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26. LAMEA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 27. LAMEA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 28. LAMEA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 29. LAMEA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30. CADWELL: COMPANY SNAPSHOT
TABLE 31. CADWELL: OPERATING SEGMENTS
TABLE 32. CADWELL: PRODUCT PORTFOLIO
TABLE 33. COMPUMEDICS: COMPANY SNAPSHOT
TABLE 34. COMPUMEDICS: OPERATING SEGMENTS
TABLE 35. DRIVE DEVILBISS HEALTHCARE: COMPANY SNAPSHOT
TABLE 36. DRIVE DEVILBISS HEALTHCARE: OPERATING SEGMENTS
TABLE 37. DRIVE DEVILBISS HEALTHCARE: PRODUCT PORTFOLIO
TABLE 38. GSK: COMPANY SNAPSHOT
TABLE 39. GSK: OPERATING SEGMENTS
TABLE 40. MERCK: COMPANY SNAPSHOT
TABLE 41. MERCK: OPERATING SEGMENTS
TABLE 42. NATUS: PRODUCT PORTFOLIO
TABLE 43. NATUS: COMPANY SNAPSHOT
TABLE 44. NATUS: OPERATING SEGMENTS
TABLE 45. PFIZER: COMPANY SNAPSHOT
TABLE 46. PFIZER: OPERATING SEGMENTS
TABLE 47. PFIZER: PRODUCT PORTFOLIO
TABLE 48. PHILIPS: COMPANY SNAPSHOT
TABLE 49. PHILIPS: OPERATING SEGMENTS
TABLE 50. PHILIPS: PRODUCT PORTFOLIO
TABLE 51. SANOFI: COMPANY SNAPSHOT
TABLE 52. SANOFI: PRODUCT PORTFOLIO
TABLE 53. SLEEPMED: COMPANY SNAPSHOT
TABLE 54. SLEEPMED: OPERATING SEGMENTS
TABLE 55. SLEEPMED: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL SLEEP AIDS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2015-2017) (%)
FIGURE 4. TOP WINNING STRATEGIES IN SLEEP AIDS MARKET (2015-2017)
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 11. TOP PLAYER POSITIONING: GLOBAL SLEEP AIDS MARKET, 2016
FIGURE 12. GLOBAL SLEEP AIDS MARKET: RESTRAINTS AND DRIVERS
FIGURE 13. GLOBAL SLEEP AIDS MARKET SEGMENTATION, BY APPLICATION
FIGURE 14. U.S. SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 16. MEXICO SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 18. FRANCE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 19. UK SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 20. ITALY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 24. AUSTRALIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 28. TURKEY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 32. CADWELL: REVENUE, 2016-2016 ($MILLION)
FIGURE 33. CADWELL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. COMPUMEDICS: REVENUE, 2016-2016 ($MILLION)
FIGURE 35. COMPUMEDICS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 36. DRIVE DEVILBISS HEALTHCARE: REVENUE, 2016-2016 ($MILLION)
FIGURE 37. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY PRODUCT TYPE, 2016 (%)
FIGURE 38. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. GSK: REVENUE, 2016-2016 ($MILLION)
FIGURE 40. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 42. MERCK: REVENUE, 2016-2016 ($MILLION)
FIGURE 43. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. NATUS: REVENUE, 2016-2016 ($MILLION)
FIGURE 46. NATUS: REVENUE SHARE BY GEOGRAPHY, 2015 (%)
FIGURE 47. PFIZER: REVENUE, 2016-2016 ($MILLION)
FIGURE 48. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. PHILIPS: REVENUE, 2016-2016 ($MILLION)
FIGURE 51. PHILIPS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 52. PHILIPS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. SANOFI: REVENUE, 2016-2016 ($MILLION)
FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 55. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. SLEEPMED: REVENUE, 2016-2016 ($MILLION)
FIGURE 57. SLEEPMED: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. SLEEPMED: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
Sleep aid products are gaining popularity due to rise in the awareness about the sleep disorders and the advancement in sleep aids technology. These products in the form of drugs and devices are used to improve the quality of sleep of the patient. Moreover, these helps in the diagnosis and treatment of sleep disorders, such as insomnia, narcolepsy, and sleep walking.
Risk of sleep disorder increases with age and obesity, thus the increase in geriatric and obese population supplements the market growth. Moreover, rise in the initiative by healthcare organization to increase awareness about the adverse effects of sleep disorder on human health, change in lifestyle, and inconsistent sleep patterns are expected to boost the market growth. However, the side effects of using sleep medication and patent expiration are expected to hamper the market growth.
The sleep laboratories segment is expected to grow at a highest rate and provide lucrative opportunities for the market players. These are used for the diagnosis and treatment of sleep disorders, and the presence of a large undiagnosed patients suffering from sleep disorder is anticipated to boost growth of this segment.
The employment of sleep aids is highest in North America, owing to the increase in adoption of these products, high awareness regarding the benefits of quality sleep among the consumers, and increase in disposable income. Although the use of sleep aids in Asia-Pacific and LAMEA region is low, the adoption rate is expected to increase, owing to rise in disposable income, presence of large geriatric and obese population.
A. The total market value of sleep aids market is $49,543 million in 2016.
A. The forecast period in the report is from 2021 to 2030
A. The market value of sleep aids market in 2023 was $79,851 million
A. The base year for the report is 2019.
A. Yes, sleep aids companies are profiled in the report
A. The top companies that hold the market share in sleep aids are Koninklijke Philips N.V., Merck & Co., Sanofi, eVilbiss Healthcare LLC., Pfizer Inc., SleepMed Inc., Cadwell Laboratories Inc., Compumedics Limited, Natus Medical Incorporated, and GlaxoSmithKline plc.
A. No, there is no value chain analysis provided in the sleep aids market report
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
